Value of blood tests including serum group IIA phospholipase A₂ and bactericidal/permeability‐increasing protein in Crohn's disease

References

• Best W. R., Becktel J. M., Singleton J. W., Kern F. J. Development of a Crohn's disease activity index. Gastroenterology 1976; 70: 439–44
   PubMed Web of Science ®Google Scholar
• Harvey R., Bradshaw J. A simple index of Crohn's disease activity. Lancet 1980; 1: 514
   PubMed Web of Science ®Google Scholar
• Andre C., Descos L., Landais P., Fermanian J. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981; 22: 571–4
   PubMed Web of Science ®Google Scholar
• Prior C., Bollbach R., Fuchs D., Hausen A., Judmaier G., Niederwieser D., et al. Urinary neopterin, a marker of clinical activity in patients with Crohn's disease. Clin Chim Acta 1986; 155: 11–22
   PubMed Web of Science ®Google Scholar
• Ekberg O., Fort F. T., Hildell J. Predictive value of small bowel radiography for recurrent Crohn's disease. Am J Radiol 1980; 135: 1051
   Google Scholar
• Andre C., Descos L., Vignal J., Gillon J. C‐reactive protein as a predictor of relapse in asymptomatic patients with Crohn's disease. Scott Med J 1983; 28: 26–9
   PubMedGoogle Scholar
• Meyers S., Lichtiger S., Feuer E. J., Lahman E. A., Janowitz H. D. Fecal alpha‐1‐antitrypsin as a measure of Crohn's disease activity. The effect of therapy and anatomical extent of disease. J Clin Gastroenterol 1988; 10: 491–7
   Google Scholar
• Minami T., Tojo H., Shinomura Y., Komatsubara T., Matsuzawa Y., Okamoto M. Elevation of phospholipase A2 protein in sera of patients with Crohn's disease and ulcerative colitis. Am J Gastroenterol 1993; 88: 1076–80
   PubMed Web of Science ®Google Scholar
• Becker K., Frieling T., Haussinger D. Quantification of fecal alpha 1‐antitrypsin excretion for assessment of inflammatory bowel diseases. Eur J Med Res 1998; 3: 65–70
   Google Scholar
• Bunn S. K., Bisset W. M., Main M. J., Golden B. E. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 32: 171–7
   PubMed Web of Science ®Google Scholar
• Nevalainen T. J., Kortesuo P. T., Rintala E., Märki F. Immunochemical detection of group I and group II phospholipases A2 in human serum. Clin Chem 1992; 38: 1824–9
   PubMed Web of Science ®Google Scholar
• Häggblom J. ‐. O., Jokilammi‐Siltanen A., Peuravuori H., Nevalainen T. Time‐resolved fluoroimmunoassay for bactericidal/permeability‐increasing protein. Mediators Inflammation 1996; 5: 47–50
   Google Scholar
• Minami T., Tojo H., Shinomura Y., Matsuzawa Y., Okamoto M. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut 1994; 35: 1593–8
   PubMed Web of Science ®Google Scholar
• Haapamäki M. M., Grönroos J. M., Nurmi H., Söderlund K., Peuravuori H., Alanen K., et al. Elevated group II phospholipase A2 mass concentrations in serum and colonic mucosa in Crohn's disease. Clin Chem Lab Med 1998; 36: 751–5
   PubMed Web of Science ®Google Scholar
• Haapamäki M. M., Grönroos J. M., Nurmi H., Irjala K., Alanen K. A., Nevalainen T. J. Phospholipase A2 in serum and colonic mucosa in ulcerative colitis. Scand J Clin Lab Invest 1999; 59: 279–87
   PubMedGoogle Scholar
• Nevalainen T. J. Serum phospholipases A2 in inflammatory diseases. Clin Chem 1993; 39: 2453–9
   PubMed Web of Science ®Google Scholar
• Haapamäki M. M., Grönroos J. M., Nurmi H., Alanen K., Kallajoki M., Nevalainen T. J. Gene expression of group II phospholipase A2 in intestine in ulcerative colitis. Gut 1997; 40: 95–101
   PubMed Web of Science ®Google Scholar
• Haapamäki M. M., Grönroos J. M., Nurmi H., Alanen K., Nevalainen T. J. Gene expression of group II phospholipase A2 in intestine in Crohn's disease. Am J Gastroenterol 1999; 94: 713–20
   PubMed Web of Science ®Google Scholar
• Kerry J. E., Marshall C., Griffiths P. A., Scott B. B., Griffiths G. White cell scanning for inflammatory bowel disease: are biochemical markers useful referral criteria?. Nucl Med Commun 2003; 24: 1145–8
   Google Scholar
• Poullis A. P., Zar S., Sundaram K. K., Moodie S. J., Risley P., Theodossi A., et al. A new, highly sensitive assay for C‐reactive protein can aid the differentiation of inflammatory bowel disorders from constipation‐ and diarrhoea‐predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002; 14: 409–12
   PubMed Web of Science ®Google Scholar
• Tibble J. A., Sigthorsson G., Bridger S., Fagerhol M. K., Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15–22
   PubMed Web of Science ®Google Scholar